GlassScriptPhysician profile
John F Keller
NPI 1770664583
$58,030.86
in general payments reported to CMS, 2019-2025
15 companies · $6,124 in 2025
The $6,124 reported for 2025 was more than what 82% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,144 · 2020: $18K · 2021: $11K · 2022: $8,354 · 2023: $2,757 · 2024: $8,234 · 2025: $6,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $10K · Food and Beverage: $5,515 · Travel and Lodging: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $10,450.14 |
| Food and Beverage | $5,514.68 |
| Travel and Lodging | $1,150.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,680.40 | 2021-2025 | Mazor X System, Catalyft Pl Expandable Interbody System, T2 Stratosphere Expandable Corpectomy System |
| Cutting Edge Spine, LLC | $14,533.92 | 2019-2025 | |
| Medtronic USA, INC. | $13,217.70 | 2019-2020 | |
| Surgalign Spine Technologies, INC. | $4,150.20 | 2019-2022 | |
| Centinel Spine, LLC | $1,302.44 | 2023 | Prodisc C Vivo, Prodisc C, Prodisc L |
| Augmedics INC. | $593.18 | 2020-2025 | Xvision |
| Carlsmed, INC. | $170.10 | 2023 | Aprevo |
| Intrinsic Therapeutics | $146.48 | 2024 | Barricaid Acd (Annular Closure Device) |
| Spineology INC. | $77.49 | 2022-2024 | Optimesh Expandable Interbody Fusion System |
| Xtant Medical INC | $48.08 | 2023 | |
| Bioventus LLC | $31.70 | 2022 | |
| Baxter Healthcare | $28.22 | 2023 | Floseal |
| Abbott Laboratories | $27.27 | 2024 | Proclaim |
| Merck Sharp & Dohme LLC | $23.68 | 2025 | Keytruda, Keytruda Qlex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,365,669.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.